COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Protocol No
ALLIANCE-A031803
Principal Investigator
Scott Johnson
Phase
II
Summary
This study is being done to answer the following question: Can we lower the chance of your bladder cancer coming back by adding the drug MK-3475 (pembrolizumab) to an existing treatment option for bladder cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.
Description
Addition of Pembrolizumab to Intravesical Chemotherapy (Gemcitabine) for the Treatment of NMIBC
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL